|
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis Clinical research trials and Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis. Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis clinical trial. Participants frequently get the best healthcare available for their Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis  Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
For Condition: Multiple Sclerosis, Relapsing-Remitting
Status: No longer recruiting
Sponsor(s): Biogen Idec , Elan Pharmaceuticals
Synopsis: The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/50 Years
Genders: Both
Protocol Entry Criteria: Male and female patients between 18 and 50 years of age who have a diagnosis of relapsing remitting multiple sclerosis.
Total Enrollment:
Location and Contact Information:
Yale University School of Medicine, Department of Neurology
New Haven, Connecticut, 06510
United States
Academisch Ziekenhuis VU
Amsterdam, , 1081 HV
Netherlands
Texas Neurology
Dallas, Texas, 75214
United States
Royal Hallamshire Hospital
Sheffield, , S10 2JF
United Kingdom
Health Services Centre
Winnipeg, Manitoba, R3A 1R9
Canada
Vancouver Hospital and Health Sciences Center UBC Pavilion, MS Clinical Research Group
Vancouver, British Columbia, V6T 2B5
Canada
MS Research Unit, Center for Clinical Research
Halifax, , B3H 1V7
Canada
CHRU - Hopital de Pontchaillou, Service de Neurologie
Rennes, , 35033
France
Faculty Hospital of Hradec Kralove
HRADEC KRALOVE, , 500 05
Czech Republic
North Staffordshire Royal Infirmary - Neurology Department
Stoke on Trent, , ST4 7LN
United Kingdom
LUC- University Centre
Diepenbeek, , 3590
Belgium
Algemeen Ziekenhuis St. Jan
Brugge, , 8000
Belgium
Kings College Hospital, Kings Neuroscience Center
London, , SE5 9RS
United Kingdom
Guy's Hospital
London, , SE1 9RT
United Kingdom
The Radcliffe Infirmary, University Department of Clinical Neurology
Oxford, , OX2 0HE
United Kingdom
Michigan Institute for Neurological Disorders
Farmington Hills, Michigan, 48335
United States
Ipswich Hospital NHS Trust - Department of Clinical Neurology
Ipswich, , IP4 5PD
United Kingdom
University of Washington MS Research Center
Seattle, Washington, 98195
United States
Atkin's Morely Hospital
Wimbledon, London, SW20 0NE
United Kingdom
Faculty Hospital St. Anne
Brno, , 656 91
Czech Republic
St. Josef-Hospital, Neurologische Klinik der Ruhruniversitat Bochum
Bochurn, , 44791
Germany
CMRRC
Albuquerque, New Mexico, 87131
United States
Hospital Pardubice - Department of Neurology
Pardubice, , 532 03
Czech Republic
Faculty Hospital Olomouc
Olomouc, , 775 20
Czech Republic
Faculty Hospital Plzen - Clinic of Neurology
Plzen, , 304 60
Czech Republic
Family Medical Centre
Ottawa, , K1N 5C7
Canada
King's College Hospital
London, , SE5 9RS
United Kingdom
Faculty Hospital Brno Bohunice
Brno, , 60200
Czech Republic
East Bay Region Associates in Neurology
Berkeley, California, 94705
United States
Institute of Neurology
Queen Square, London, WC1N 3BG
United Kingdom
Lehigh Valley Hospital, Neurosciences Research
Allentown, Pennsylvania, 18103
United States
Kingston General Hospital, Neurology
Kingston, Ontario, K7L 2V7
Canada
Faculty Hospital Motol - Neurological Clinic
Prague, , 5 105 06
Czech Republic
Royal Victoria Infirmary
Newcastle upon Tyne, , NE1 4LP
United Kingdom
General Teaching Hospital - Neurological Department
Prague, , 2 12802
Czech Republic
Faculty Hospital Of Ostrava Poruba
Ostrava, , 70852
Czech Republic
University of Nebraska Medical Center
Omaha, Nebraska, 68198
United States
University of Toronto, MS Clinic, St. Michael's Hospital
Toronto, Ontario, M5B 1W8
Canada
Sunnybrook and Women's College and Health Science Centre
Toronto, Ontario, M4N 3M5
Canada
Hopital de la Timone, Service de Neurologie
Marseille, , 13385
France
Gimbel MS Center
Teaneck, New Jersey, 07666
United States
CHVO Hull Hospital
Quebec City, Quebec, J8Y 1W7
Canada
Klinika Neurologii
Bydgoszcz, , 85-681
Germany
University Hospital
London, Ontario, N6A 5A5
Canada
Oldchurch Hospital
Essex, , NE1 4LP
United Kingdom
National MS Centrum
Melsbroek, , 1820
Belgium
Mayo Clinic Scottsdale
Scottsdale, Arizona, 85259
United States
St. James University Hospital, Department of Neurology
Leeds, , LS9 7TF
United Kingdom
UC Davis School of Medicine, Department of Neurology
Davis, California, 95817-2307
United States
University of Miami School of Medicine, Department of Neurology
Miami, Florida, 33136
United States
The Royal London Hospital
Whitechapel, London, E1 1BB
United Kingdom
Oregon Health Sciences University, Department of Neurology
Portland, Oregon, 97201-3098
United States
University of Kansas Medical Center, Department of Neurology
Kansas City, Kansas, 66160
United States
Additional Information:
Study ID Numbers: C-1801;
Study Start Date: November 2001
Record last reviewed: January 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00027300
Other Multiple Sclerosis, Relapsing-Remitting Studies:
1. Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
2. Safety of RG2077 in Patients With Multiple Sclerosis
3. Treatment of Multiple Sclerosis using Over the Counter Inosine
4. Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
5. A Phase II Study Comparing Low- and High-Dose CAMPATH and High-Dose Rebif in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Related Studies:
Other Multiple Sclerosis, Relapsing-Remitting Clinical Trials
Other London Clinical Trials
Other Queen Square Clinical Trials
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
|
|
|
|
|
|
|
|
